Cover Image
市場調查報告書

躁鬱症治療藥的全球市場:2015年∼2019年

Global Biopolar Disorder Therapeutics Market 2015-2019

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 347447
出版日期 內容資訊 英文 94 Pages
訂單完成後即時交付
價格
Back to Top
躁鬱症治療藥的全球市場:2015年∼2019年 Global Biopolar Disorder Therapeutics Market 2015-2019
出版日期: 2015年12月16日 內容資訊: 英文 94 Pages
簡介

全球躁鬱症治療藥市場,預計2014年∼2019年以2.24%的年複合成長率成長。

本報告提供全球躁鬱症治療藥市場相關調查分析、市場規模與成長率、市場趨勢、市場的推動要素與課題、市場機會驗證、主要供應商等相關的系統性資訊。

第1章 摘要整理

第2章 調查範圍

  • 市場概要
  • 主要供應商產品

第3章 市場調查手法

  • 調查手法
  • 經濟指標

第4章 簡介

  • 主要市場焦點

第5章 疾病概要

  • 疾病的理解
  • 躁鬱症的種類
  • 原因
  • 徵兆與症狀
  • 管理
  • 自助
  • 流行病學

第6章 開發平台分析

  • ITI-007
  • FK949E
  • PROCYCLOX
  • RP5603
  • CNV1061436
  • LY2979165
  • DP-VPA
  • SKL-PSY
  • PGW-5
  • DLP-114
  • DLP-115
  • Small molecule targeting GPR78

第7章 市場形勢

  • 市場概要
  • 市場規模與預測
  • 波特的五力分析

第8章 市場區隔:各藥物分類

第9章 市場區隔:各作用機制

第10章 地理區分

  • 各地理分類
  • 南北美洲
  • 歐洲、中東、非洲
  • 亞太地區

第11章 推動市場要素

第12章 推動因素的影響

第13章 市場課題

第14章 推動因素與課題的影響

第15章 市場趨勢

第16章 業者情勢

  • 競爭模式
  • 市場佔有率分析
  • 其他卓越供應商

第17章 主要供應商分析

  • Allergan
  • AstraZeneca
  • BMS
  • Eli Lilly
  • GSK
  • Janssen Pharmaceuticals

第18章 附錄

  • 簡稱清單

第19章 關於Technavio

圖表

目錄
Product Code: IRTNTR7311

About bipolar disorder therapeutics

Bipolar disorder is a psychological disorder characterized by intermittent mood swings. The individual suffering with this disorder experiences extreme poles of either mania or depression or both. The disorder severely affects the personal, social, and professional life of an individual. The symptoms usually include drastic changes in mood, either as a manic episode or a depressive episode. There is no complete cure for the disorder. Atypical antipsychotics, mood stabilizers, and antidepressants are being widely used in for treatment. It is considered as a lifelong disease and the discontinuation of the medication can lead to relapse of the condition.

Technavio's analysts forecast the global bipolar disorder therapeutics market to grow at a CAGR of 2.24% over the period 2014-2019.

Covered in this report

The report covers the present scenario and growth prospects of the global bipolar disorder therapeutics market for 2015-2019. To calculate the market size, the report considers the revenue generated from the sales of prescription, generic, and off-label drugs used in the treatment of bipolar disorder.

Technavio's report, Global Bipolar Disorder Therapeutics Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers Americas, APAC, and EMEA; it also covers the landscape of the global bipolar disorder therapeutics market and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.

Key regions

  • Americas
  • APAC
  • EMEA

Key vendors

  • Allergan
  • AstraZeneca
  • BMS
  • Eli Lilly
  • GlaxoSmithKline
  • Janssen Pharmaceuticals

Other Prominent Vendors

  • AbbVie
  • Abital Pharma
  • Astellas
  • Convergence Pharmaceuticals
  • D Pharm
  • Delpor
  • Gedeon Richter
  • H. Lundbeck
  • Intra-Cellular Therapies
  • Novartis
  • Noven Pharmaceuticals
  • Omeros Corporation
  • Otsuka
  • Pfizer
  • PNBDevCo
  • Reviva Pharmaceuticals
  • SK Biopharmaceuticals
  • Sunovion Pharmaceutical

Key market driver

  • Increase in prevalence of bipolar disorder
  • For a full, detailed list, view our report

Key market challenge

  • Use of alternative therapies
  • For a full, detailed list, view our report

Key market trend

  • Rise in public awareness
  • For a full, detailed list, view our report

Key questions answered in this report

  • What will the market size be in 2019 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

Table of Contents

PART 01: Executive summary

  • Highlights

PART 02: Scope of the report

  • Market overview
  • Top-vendor offerings

PART 03: Market research methodology

  • Research methodology
  • Economic indicators

PART 04: Introduction

  • Key market highlights

PART 05: Disease overview

  • Understanding the disorder
  • Types of bipolar disorder
  • Causes
  • Signs and symptoms
  • Management
  • Self-help
  • Epidemiology

PART 06: Pipeline analysis

  • ITI-007
  • FK949E
  • PROCYCLOX
  • RP5603
  • CNV1061436
  • LY2979165
  • DP-VPA
  • SKL-PSY
  • PGW-5
  • DLP-114
  • DLP-115
  • Small molecule targeting GPR78

PART 07: Market landscape

  • Market overview
  • Market size and forecast
  • Five forces analysis

PART 08: Market segmentation by drug class

  • Mood stabilizers
  • Anticonvulsants
  • Atypical antipsychotics
  • Antidepressant drugs
  • Anti-anxiety drugs

PART 09: Market segmentation by mechanism of action

  • Selective serotonin reuptake inhibitors
  • Serotonin-norepinephrine reuptake inhibitors
  • Tricyclic antidepressants
  • Monoamine oxidase inhibitors
  • Benzodiazepines
  • Beta blockers
  • Others

PART 10: Geographical segmentation

  • Global bipolar disorder therapeutics market by geographical segmentation 2014-2019
  • Bipolar disorder therapeutics market in Americas
  • Bipolar disorder therapeutics market in EMEA
  • Bipolar disorder therapeutics market in APAC

PART 11: Market drivers

  • Increase in prevalence of bipolar disorder
  • High unmet need
  • Increase in R&D

PART 12: Impact of drivers

PART 13: Market challenges

  • Use of alternative therapies
  • Lack of availability of standard diagnostic methods
  • Limited awareness of disease
  • Increase in patent expiries

PART 14: Impact of drivers and challenges

PART 15: Market trends

  • Rise in public awareness
  • Patient assistance programs
  • Strategic alliances

PART 16: Vendor landscape

  • Competitive scenario
  • Market share analysis 2014
  • Other prominent vendors

PART 17: Key vendor analysis

  • Allergan
  • AstraZeneca
  • BMS
  • Eli Lilly
  • GSK
  • Janssen Pharmaceuticals

PART 18: Appendix

  • List of abbreviatios

PART 19: Explore Technavio

List of Exhibits

  • Exhibit 01: Product offerings
  • Exhibit 02: Signs and symptoms of bipolar disorder
  • Exhibit 03: Signs and symptoms of mania
  • Exhibit 04: Signs and symptoms of depression
  • Exhibit 05: Treatment options for bipolar disorder
  • Exhibit 06: Medications for treating bipolar disorder
  • Exhibit 07: Global bipolar disorder therapeutics market: Pipeline portfolio
  • Exhibit 08: Global bipolar disorder therapeutics market 2014-2019 ($ millions)
  • Exhibit 09: Five forces analysis
  • Exhibit 10: Segmentation of global bipolar disorder therapeutics market by drug class
  • Exhibit 11: Global bipolar disorder therapeutics market segment by geography 2014
  • Exhibit 12: Bipolar disorder therapeutics market revenue by geography 2014-2014 ($ millions)
  • Exhibit 13: Bipolar disorder therapeutics market in Americas 2014-2019 ($ millions)
  • Exhibit 14: Bipolar disorder therapeutics market in EMEA 2014-2019 ($ millions)
  • Exhibit 15: Bipolar disorder therapeutics market in APAC 2014-2019 ($ millions)
  • Exhibit 16: Impact of drivers
  • Exhibit 11: Common disorders that co-exist with bipolar disorder
  • Exhibit 17: Impact of drivers and challenges
  • Exhibit 18: Market share analysis of global bipolar disorder therapeutics market 2014
  • Exhibit 19: YoY growth rate of major bipolar disorder drugs 2014-2019 ($ millions)
  • Exhibit 20: Bristol-Myers Squibb: YoY growth and revenue generated from net product sales of Abilify 2011-2014 ($ millions)
  • Exhibit 21: Bristol-Myers Squibb: Percentage share of Abilify in US and non-US region based on revenue 2014
  • Exhibit 22: Bristol-Myers Squibb: Key takeaways
  • Exhibit 23: AstraZeneca: YoY growth and revenue generated from net product sales of Seroquel XR 2011-2014 ($ millions)
  • Exhibit 24: AstraZeneca: Revenue generated from sales of Seroquel XR by region 2014 ($ millions)
  • Exhibit 25: AstraZeneca: YoY growth and revenue generated from net product sales of Seroquel IR 2011-2014 ($ millions)
  • Exhibit 26: AstraZeneca: Key takeaways
  • Exhibit 27: Janssen Pharmaceuticals: YoY growth and revenue generated from net product sales of Risperdal Consta 2011-2014 ($ millions)
  • Exhibit 28: Janssen Pharmaceuticals: Key takeaways
  • Exhibit 29: Eli Lilly: YoY growth and revenue generated from net product sales of Zyprexa 2011-2014 ($ millions)
  • Exhibit 30: Eli Lilly: Key takeaways
  • Exhibit 31: GlaxoSmithKline: YoY growth and revenue generated from net product sales of Lamictal 2011-2014 ($ millions)
  • Exhibit 32: GlaxoSmithKline: Revenue generated from sales of Lamictal by region 2014 ($ millions)
  • Exhibit 33: GlaxoSmithKline: Key takeaways
  • Exhibit 34: Allergan: Key takeaways
  • Exhibit 35: Allergan: Business segmentation by product revenue 2014
  • Exhibit 36: Allergan: Business segmentation by revenue 2013 and 2014 ($ billions)
  • Exhibit 37: Allergan: Geographical segmentation by revenue 2014
  • Exhibit 38: AstraZeneca: Business segmentation by revenue 2014
  • Exhibit 39: AstraZeneca: Business segmentation by revenue 2013 and 2014
  • Exhibit 40: AstraZeneca: Geographical segmentation by revenue 2014
  • Exhibit 41: BMS: Segmentation by revenue 2014
  • Exhibit 42: BMS: Segmentation by revenue 2013 and 2014 ($ billions)
  • Exhibit 43: BMS: Geographical segmentation by revenue 2014
  • Exhibit 44: Lilly: Business segmentation by revenue 2014
  • Exhibit 45: Eli Lilly: Business segmentation by revenue 2013 and 2014 ($ billions)
  • Exhibit 46: Eli Lilly: Geographical segmentation by revenue 2014
  • Exhibit 47: GSK: Business segmentation by revenue 2014
  • Exhibit 48: GSK: Business segmentation by revenue 2013 and 2014 ($ billions)
  • Exhibit 49: GSK: Geographical segmentation by revenue 2014
  • Exhibit 50: Janssen Pharmaceuticals: Key therapeutic areas
Back to Top